a current prediction, page-27

Autoimmune progress is certainly glacial but I doubt they would deliberately hold it back, its too valuable. Triebel has been very positive about its potential. It’s a bit odd that they are not talking about it. The only thing they have said recently is that contract manufacturing is being organized and there will be an “ update” in 2022, just a few scraps buried deep in the press releases.
My view is that they are moving ahead with it as fast as they can but are deliberately holding back on the excitement and keeping the focus on Efti. Maybe a case of keeping some powder in reserve for a rainy day or if they need something to pump the share price ahead of a raise.
At this point there’s no indication that it will be in the clinic next year.